Outcomes in COVID-19 nitazoxanide studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​1 ​ Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 Tau​2 ​ = 1.35; I​2 ​ = 77.4% Early treatment 49% 0.51 [0.13-1.95] 10/820 46/594 49% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment 67% 0.33 [0.07-1.50] 2/25 6/25 67% improvement All studies 55% 0.45 [0.15-1.35] 12/845 52/619 55% improvement 6 nitazoxanide COVID-19 studies c19nitazoxanide.com Oct 20, 2021 ​1 ​ CT: study uses combined treatment Tau​2 ​ = 1.03; I​2 ​ = 71.7%; Z = 1.42 Effect extraction pre-specified Favors nitazoxanide Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani 88% 0.12 [0.01-2.52] 0/357 2/137 Improvement, RR [CI] Treatment Control Rossignol (DB RCT) -206% 3.06 [0.13-74.6] 1/184 0/195 Tau​2 ​ = 2.67; I​2 ​ = 51.4% Early treatment 41% 0.59 [0.02-13.8] 1/541 2/332 41% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] 2/25 6/25 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment 67% 0.33 [0.07-1.50] 2/25 6/25 67% improvement All studies 60% 0.40 [0.10-1.58] 3/566 8/357 60% improvement 3 nitazoxanide COVID-19 mortality results c19nitazoxanide.com Oct 20, 2021 Tau​2 ​ = 0.17; I​2 ​ = 9.3%; Z = 1.31 Favors nitazoxanide Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] 2/194 0/198 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment -404% 5.04 [0.24-104] 2/194 0/198 -404% improvement All studies -404% 5.04 [0.24-104] 2/194 0/198 -404% improvement 1 nitazoxanide COVID-19 ICU result c19nitazoxanide.com Oct 20, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 1.05 Favors nitazoxanide Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -2% 1.02 [0.30-3.47] hosp. 5/194 5/198 Improvement, RR [CI] Treatment Control Cadegiani 99% 0.01 [0.00-0.17] hosp. 0/357 27/137 Rossignol (DB RCT) 79% 0.21 [0.02-1.80] hosp. 1/184 5/195 Tau​2 ​ = 3.68; I​2 ​ = 78.4% Early treatment 83% 0.17 [0.01-2.00] 6/735 37/530 83% improvement Blum (DB RCT) 56% 0.44 [0.22-0.89] hosp. time 25 (n) 25 (n) Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment 56% 0.44 [0.22-0.89] 0/25 0/25 56% improvement All studies 71% 0.29 [0.08-1.06] 6/760 37/555 71% improvement 4 nitazoxanide COVID-19 hospitalization results c19nitazoxanide.com Oct 20, 2021 Tau​2 ​ = 1.06; I​2 ​ = 67.6%; Z = 1.88 Favors nitazoxanide Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 Tau​2 ​ = 1.71; I​2 ​ = 40.9% Early treatment -21% 1.21 [0.12-12.3] 3/735 2/530 -21% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment 67% 0.33 [0.07-1.50] 2/25 6/25 67% improvement All studies 31% 0.69 [0.15-3.29] 5/760 8/555 31% improvement 4 nitazoxanide COVID-19 serious outcomes c19nitazoxanide.com Oct 20, 2021 Tau​2 ​ = 0.88; I​2 ​ = 33.9%; Z = 0.46 Effect extraction pre-specified Favors nitazoxanide Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) 12% 0.88 [0.80-0.96] viral+ 194 (n) 198 (n) Improvement, RR [CI] Treatment Control Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​1 ​ Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Tau​2 ​ = 0.78; I​2 ​ = 92.8% Early treatment 54% 0.46 [0.16-1.30] 7/279 44/262 54% improvement Blum (DB RCT) 90% 0.10 [0.01-1.78] viral+ 0/23 4/19 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment 90% 0.10 [0.01-1.78] 0/23 4/19 90% improvement All studies 60% 0.40 [0.15-1.09] 7/302 48/281 60% improvement 4 nitazoxanide COVID-19 viral clearance results c19nitazoxanide.com Oct 20, 2021 ​1 ​ CT: study uses combined treatment Tau​2 ​ = 0.79; I​2 ​ = 89.9%; Z = 1.79 Favors nitazoxanide Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 Tau​2 ​ = 0.09; I​2 ​ = 6.3% Early treatment 8% 0.92 [0.41-2.08] 3/401 0/406 8% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment 67% 0.33 [0.07-1.50] 2/25 6/25 67% improvement All studies 25% 0.75 [0.36-1.55] 5/426 6/431 25% improvement 4 nitazoxanide COVID-19 Randomized Controlled Trials c19nitazoxanide.com Oct 20, 2021 Tau​2 ​ = 0.09; I​2 ​ = 11.3%; Z = 0.78 Effect extraction pre-specified Favors nitazoxanide Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rossignol (DB RCT) -206% 3.06 [0.13-74.6] 1/184 0/195 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment -206% 3.06 [0.13-74.6] 1/184 0/195 -206% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] 2/25 6/25 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment 67% 0.33 [0.07-1.50] 2/25 6/25 67% improvement All studies 37% 0.63 [0.09-4.54] 3/209 6/220 37% improvement 2 nitazoxanide COVID-19 RCT mortality results c19nitazoxanide.com Oct 20, 2021 Tau​2 ​ = 0.84; I​2 ​ = 34.0%; Z = 0.45 Favors nitazoxanide Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​1 ​ Tau​2 ​ = 2.14; I​2 ​ = 62.4% Early treatment 68% 0.32 [0.04-2.58] 9/613 46/386 68% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment 67% 0.33 [0.07-1.50] 2/25 6/25 67% improvement All studies 73% 0.27 [0.08-0.94] 11/638 52/411 73% improvement 4 nitazoxanide COVID-19 peer reviewed trials c19nitazoxanide.com Oct 20, 2021 ​1 ​ CT: study uses combined treatment Tau​2 ​ = 0.76; I​2 ​ = 51.1%; Z = 2.06 Effect extraction pre-specified Favors nitazoxanide Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Rocco (RCT) -2% 1.02 [0.30-3.47] hosp. 5/194 5/198 Rocco (RCT) -16% 1.16 [0.84-1.59] no recov. 59/194 52/198 Rocco (RCT) 12% 0.88 [0.80-0.96] viral+ 194 (n) 198 (n) Rocco (RCT) 14% 0.86 [0.77-0.96] viral+ 136/194 162/198 Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Cadegiani 97% 0.03 [0.00-0.51] ventilation 0/357 9/137 Cadegiani 99% 0.01 [0.00-0.17] hosp. 0/357 27/137 Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​1 ​ Elalfy 58% 0.42 [0.31-0.56] viral+ 26/62 51/51 CT​1 ​ Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Silva (SB RCT) 38% 0.62 [0.39-0.97] viral+ 12/23 11/13 Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 Rossignol (DB RCT) 79% 0.21 [0.02-1.80] hosp. 1/184 5/195 Rossignol (DB RCT) 85% 0.15 [0.02-1.22] severe case 1/184 7/195 Rossignol (DB RCT) 84% 0.16 [0.02-1.29] severe case 1/112 7/126 Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Blum (DB RCT) 62% 0.38 [0.11-1.25] ventilation 3/25 8/25 Blum (DB RCT) 56% 0.44 [0.22-0.89] hosp. time 25 (n) 25 (n) Blum (DB RCT) 90% 0.10 [0.01-1.78] viral+ 0/23 4/19 nitazoxanide COVID-19 outcomes c19nitazoxanide.com Oct 20, 2021 Favors nitazoxanide Favors control
Please send us corrections, updates, or comments.
Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC .
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
